CORMEDIX INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations
CORMEDIX INC. (CRMD) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations of $43.82 million as of 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations · last filed 2024-03-12
- 2023-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $43.82M.
- 2023-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $19.89M.
- 2023-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $25.50M.
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $43.37M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations |
|---|---|
| 2023-12-31 | $43.82M 10-K · filed 2024-03-12 |
| 2023-06-30 | $19.89M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $25.50M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $43.37M 10-K · filed 2024-03-12 |
| 2022-09-30 | $43.47M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $49.15M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $45.62M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $53.55M 10-K · filed 2023-03-30 |
| 2021-09-30 | $66.55M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $73.33M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $76.45M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $42.10M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |